Skip to main content
. 2020 Mar 10;26:e921594-1–e921594-15. doi: 10.12659/MSM.921594

Figure 3.

Figure 3

Silencing of lncRNA MSC-AS1 makes OS cells more sensitive to cisplatin. (A) lncRNA MSC-AS1 expression in transfected U2OS cells and U2OS/DDP cells was detected by RT-qPCR. (B) U2OS and U2OS/DDP cell viabilities in different DDP concentrations (0, 2, 4, 8, 16, 32, 64 ug/mL) were measured by MTT assay. (C) U2OS cell colony formation ability treated by 4 μg/mL DDP and U2OS/DDP cell colony formation ability treated by 8 μg/mL DDP were assessed by colony formation assay. (D) U2OS cell apoptosis treated with 4 μg/mL DDP and U2OS/DDP cell apoptosis treated with 8 μg/mL DDP was detected by flow cytometry. Compared with control group, * p<0.05, ** p<0.01, the experiments were performed 3 times, one-way ANOVA and the t test were applied to determine (A, C, D), and two-way ANOVA and Tukey’s multiple comparisons test were applied to determine (B). lncRNA – long non-coding RNA; OS – osteosarcoma; RT-qPCR – reverse transcription-quantitative polymerase chain reaction; MTT – 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide; ANOVA – analysis of variance.